Trial Profile
OGF and Gemcitabine: Novel Treatment for Pancreatic Cancer Phase I, A Safety and Toxicity Study.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 Sep 2018
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Methionine enkephalin (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 18 May 2011 Planned end date changed from Jun 2011 to Oct 2011 as reported by ClinicalTrials.gov.
- 31 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 May 2009 Planned end date (Jun 2011) added as reported by ClinicalTrials.gov.